Robert B. Levy, Ph.D., is a member of the Sylvester Comprehensive Cancer Center at the University of Miami, Miller School of Medicine. He is a professor of Microbiology and Immunology, and Ophthalmology and Medicine, and previously served as graduate program chair for 19 years within the Microbiology and Immunology department. Dr. Levy's research has been focused on developing approaches to facilitate the success of hematopoietic stem ('bone marrow') cell transplants (HSCT) by inhibiting graft-versus-host disease (GVHD) while promoting graft-versus-leukemia (GVL). His laboratory has generated a novel Treg expansion strategy via concomitant stimulation of both the TNFRFS25 and IL-2 receptors. Current studies involve the development of combinatorial protocols to inhibit activation of antigen-reactive T-cells; employing Treg cells, MEK pathway inhibitors and epigenetic transcriptional regulators; the regulation of innate immune sensors; and generating localized therapeutic modalities to treat ocular GVHD. Dr. Levy has authored more than 130 original papers, contributed to book chapters, served on study review panels, and is currently associate editor for the journals, 'Biology of Blood and Marrow Transplantation' and 'Bone Marrow Research.' He was an American Cancer Society fellow and a senior staff fellow at the National Cancer Institute, Bethesda, MD. He received his M.Sc. and Ph.D. at Ohio State University and his undergraduate degree from Muhlenberg College.
Robert S. Negrin, M.D. is a professor of medicine and Division Chief of Blood and Marrow Transplantation at Stanford University. His research work focuses on cellular immunology; in particular, developing a more fundamental understanding of complex biological reactions, such as graft versus host (GVHD) and graft versus tumor (GFT) reactions within the clinic and in animal models. Dr. Negrin is a member of the Association of American Physicians and the founding editor of 'Blood Advances.' Additionally, he has authored more than 225 original papers, 40 book chapters, as well as a book, and once served as associate editor of the journal, 'Blood.' He is also the recipient of a number of awards, including the Doris Duke Distinguished Clinical Scientist Award. Previously, he was president of both the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation. Dr. Negrin received his M.D. from Harvard University and trained in medicine and hematology at Stanford University, where he joined the faculty in 1990. He received his undergraduate degree from the University of California at Berkeley.
Dr. Tolcher is a medical oncologist who has more than 25 years of early drug development and clinical trial experience and is currently a principal investigator for 20 Phase 1 clinical studies. He is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology; and has chaired the Developmental Therapeutics Review Committee for the American Society for Clinical Oncology Annual Scientific Program. In addition, he is a member of more than 20 scientific advisory boards for both large and small pharmaceutical companies and serves as a board member for two biotechnology companies.
Dr. Tolcher has been involved in many of the initial Phase 1 studies of new agents that subsequently were FDA approved for the treatment of cancer. Some of these include pembrolizumab (Keytruda®), copanlisib (Aliqopa®), trastuzumab emtansine (Kadcyla®), regorafenib (Stivarga®), liposomal vincristine (Marqibo®), cabazitaxel (Jevtana®), carfilzomib (Kyprolis®), gefitinib (Iressa®), erlotinib (Tarceva®) and eribulin (Halaven®).
Dr. Tolcher is CEO and founder of NEXT Oncology, a San Antonio-based company focused on accelerating breakthrough medicines for cancer by developing and supporting Phase 1 clinical trial programs in oncology research. In 2007, Dr. Tolcher co-founded South Texas Accelerated Research Therapeutics (START), which operates one of the world's largest Phase 1 and early drug development oncology programs. He served as president of the company until 2018.
Dr. Tolcher has over 100 peer-reviewed publications in scientific journals, such as Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology and Clinical Cancer Research, and he is an author of nine book chapters.